Department of General, Vascular and Thoracic Surgery, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, D-12200 Berlin, Germany.
Oncol Rep. 2012 Nov;28(5):1619-24. doi: 10.3892/or.2012.1968. Epub 2012 Aug 10.
Colorectal cancer is one of the leading causes of cancer-related death worldwide. Molecular biomarkers could help to predict patient outcome and to identify patients who benefit from adjuvant therapy. Pontin and Reptin are ATPases which are involved in transcriptional regulation, DNA damage repair and regulation of cell proliferation. Many interaction partners of Pontin and Reptin such as β-catenin and c-myc are important factors in carcinogenesis. We hypothesized that Pontin and Reptin expression may be a negative predictor for survival in colorectal carcinoma. Specimens from 115 patients with primary colon adenocarcinomas UICC stage III and primary rectal adenocarcinomas UICC stage II and III curatively resected at the Department of Surgery, Charité Berlin, were evaluated. Clinical follow-up data were complete and mean follow-up time of patients was 51.8 months. We evaluated the expression of Pontin, Reptin and Ki-67 by immunohistochemistry. Patients with Pontin-positive carcinomas showed no differences in recurrence-free survival (p=0.109) and overall survival (p=0.197). There were no differences in Reptin-positive carcinomas and Ki-67-positive carcinomas in recurrence-free survival (p=0.443 and p=0.160) and overall survival (p=0.477 and p=0.687). Patients with Pontin-positive colorectal carcinomas receiving adjuvant therapy had a significantly worse recurrence-free survival (p=0.008) and overall survival (p=0.011) than Pontin-negative patients with adjuvant therapy. In UICC stage III, Pontin-positive colorectal carcinomas had a significantly worse recurrence-free survival (p=0.028). Pontin-positivity seems to be a negative predictor for response to adjuvant therapy in colorectal cancer patients and may help to identify patients with adverse outcome in advanced tumor stages.
结直肠癌是全球癌症相关死亡的主要原因之一。分子生物标志物可帮助预测患者的预后，并确定受益于辅助治疗的患者。Pontin 和 Reptin 是参与转录调控、DNA 损伤修复和细胞增殖调节的 ATP 酶。Pontin 和 Reptin 的许多相互作用伙伴，如β-catenin 和 c-myc，都是致癌作用的重要因素。我们假设 Pontin 和 Reptin 的表达可能是结直肠癌患者生存的负预测因子。在 Charité Berlin 外科系，评估了 115 例经手术根治性切除的原发性结肠腺癌 UICC 分期 III 期和原发性直肠腺癌 UICC 分期 II 期和 III 期患者的标本。临床随访资料完整，患者的平均随访时间为 51.8 个月。我们通过免疫组织化学评估了 Pontin、Reptin 和 Ki-67 的表达。Pontin 阳性癌患者在无复发生存率（p=0.109）和总生存率（p=0.197）方面无差异。Reptin 阳性癌和 Ki-67 阳性癌在无复发生存率（p=0.443 和 p=0.160）和总生存率（p=0.477 和 p=0.687）方面无差异。接受辅助治疗的 Pontin 阳性结直肠癌患者的无复发生存率（p=0.008）和总生存率（p=0.011）明显低于接受辅助治疗的 Pontin 阴性患者。在 UICC 分期 III 期，Pontin 阳性结直肠癌患者的无复发生存率（p=0.028）明显更差。Pontin 阳性似乎是结直肠癌患者对辅助治疗反应的负预测因子，并可能有助于识别晚期肿瘤阶段预后不良的患者。
